Technical Analysis for IMGN - ImmunoGen, Inc.

Grade Last Price % Change Price Change
grade F 1.99 3.11% 0.06
IMGN closed up 3.11 percent on Friday, May 24, 2019, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical IMGN trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 3.11%
Narrow Range Bar Range Contraction 3.11%
NR7 Range Contraction 3.11%
Wide Bands Range Expansion 3.11%

Older signals for IMGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Biotechnology Clinical Medicine Drugs Solid Tumors Monoclonal Antibodies Non Small Cell Lung Cancer Ovarian Cancer Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Antibody Drug Conjugates Clinical Trial Product Metastatic Breast Cancer NHL Amgen Immunogen Its Its Products Her2 Metastatic Small Cell Lung Cancer
Is IMGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.31
52 Week Low 1.88
Average Volume 3,455,949
200-Day Moving Average 5.4633
50-Day Moving Average 2.5778
20-Day Moving Average 2.548
10-Day Moving Average 2.214
Average True Range 0.2304
ADX 32.63
+DI 14.5984
-DI 31.0357
Chandelier Exit (Long, 3 ATRs ) 2.7788
Chandelier Exit (Short, 3 ATRs ) 2.5712
Upper Bollinger Band 3.6149
Lower Bollinger Band 1.4811
Percent B (%b) 0.24
BandWidth 83.744113
MACD Line -0.2252
MACD Signal Line -0.1361
MACD Histogram -0.0891
Fundamentals Value
Market Cap 178.3 Million
Num Shares 89.6 Million
EPS -1.22
Price-to-Earnings (P/E) Ratio -1.63
Price-to-Sales 5.58
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.16
Resistance 3 (R3) 2.14 2.06 2.13
Resistance 2 (R2) 2.06 2.02 2.07 2.12
Resistance 1 (R1) 2.03 2.00 2.05 2.05 2.11
Pivot Point 1.95 1.95 1.96 1.96 1.95
Support 1 (S1) 1.92 1.91 1.94 1.94 1.87
Support 2 (S2) 1.84 1.89 1.85 1.86
Support 3 (S3) 1.81 1.84 1.85
Support 4 (S4) 1.83